[1] TANSLEY S L, SIMOU S, SHADDICK G, et al. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun, 2017, 84: 55-64. [2] RIDER L G, NISTALA K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med, 2016, 280(1): 24-38. [3] 李珊珊, 葛永鹏, 杨阚波, 等. 皮肌炎患者427例肌炎特异性抗体谱及与临床特征相关性分析. 中华风湿病学杂志, 2017, 21(9): 585-594. [4] 李冬梅, 汪利, 刘明月, 等. 幼年皮肌炎临床特征与肌炎抗体相关性分析. 中华儿科杂志, 2020, 58(12) : 966-972. [5] BOHAN A, PETER J B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 1975, 292(7): 344-347. [6] LUNDBERG I E, TJARNLUND A, BOTTAI M, et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol, 2017, 69(12): 2271-2282. [7] LUNDBERG I E, TJARNLUND A, BOTTAI M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis, 2017, 76(12): 1955-1964. [8] SAG E, DEMIR S, BILGINER Y, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Semin Arthritis Rheum, 2021, 51(1): 95-100. [9] KHOJAH A, LIU V, SAVANI SI, et al. Studies of 96 children with Juvenile Dermatomyositis: P155/140, is associated with loss of nailfold capillaries, but not generalized lipodystrophy. Arthritis Care Res (Hoboken), 2020, doi: 10. 1002/acr. 24535. [10] IWATA N, NAKASEKO H, KOHAGURA T, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Mod Rheumatol, 2019, 29(5): 802-807. [11] MATSUSHITA T, MIZUMAKI K, KANO M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol, 2017, 176(2): 395-402. [12] TANSLEY SL, BETTERIDGE ZE, SHADDICK G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford), 2014, 53(12): 2204-2208. [13] AOUIZERATE J, DE ANTONIO M, BADER-MEUNIER B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford), 2018, 57(5): 873-879. [14] BEST M, MOLINARI N, CHASSET F, et al. Use of anti-transcriptional intermediary factor-1 Gamma autoantibody in identifying adult dermatomyositis patients with cancer: A systematic review and meta-analysis. Acta Derm Venereol, 2019, 99(3): 256-262. [15] TRALLERO-ARAGUAS E, RODRIGO-PENDAS JA, SELVA-O'CALLAGHAN A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum, 2012, 64(2): 523-532. [16] GONO T, SATO S, KAWAGUCHI Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford), 2012, 51(9): 1563-1570. [17] HUANG K, VINIK O, SHOJANIA K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int, 2019, 39(11): 1971-1981. [18] MOTEGI S I, SEKIGUCHI A, TOKI S, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol, 2019, 29(5): 511-517. [19] SATO S, UEJIMA Y, NANBU M, et al. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. Mod Rheumatol, 2017, 27(4): 652-656. [20] KOBAYASHI N, TAKEZAKI S, KOBAYASHI I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford), 2015, 54(5): 784-791. [21] LIAN X, ZOU J, GUO Q, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: The FLAIR model. Chest, 2020, 158(4): 1535-1545. [22] YAMAGUCHI K, YAMAGUCHI A, KASHIWAGI C, et al. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med, 2018, 140: 1-5. [23] CHEN F, ZUO Y, LI S, et al. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center. Respir Med, 2019, 155: 127-132 |